----
Current ValuationThe current P/E ratio is -0.11, above the reasonable range, cheaper than 0.84% of the time in the past 5 years, and the industry ranks 75/257, the industry Median -1.02.
-0.114xP/E
$0.40Stock price
$-3.56Earnings per share
-0.114xP/E
Stock price$0.40Earnings per share$-3.56
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -4.62x
- Typical range
- -6.37x–-2.44x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
03876114152
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
BAYZFUSBayer Aktiengesellschaft | -37.44x | -- | $62.24B |
BAYRYUSBayer | -37.78x | -- | $62.80B |
VTRSUSViatris | -39.33x | 97.55% | $23.90B |
ELANUSElanco Animal Health | -90.99x | 146.23% | $13.38B |
ABVXUSAbivax SA | -16.87x | 22.99% | $7.85B |
AXSMUSAxsome Therap | -47.14x | 29.75% | $7.42B |
CURLFUSCuraleaf Holdings, Inc. | -331.19x | -- | $6.84B |
VREOFUSVIREO GROWTH INC | -94.54x | -- | $6.35B |
BLTEUSBelite Bio | -61.58x | 29.87% | $6.30B |
MANEUSVeraDermics | -57.98x | 97.44% | $6.20B |
DFTXUSDefinium Therapeutics | -13.79x | 43.38% | $4.65B |
LQDAUSLiquidia Tech | -48.85x | 354.53% | $4.60B |
AMLXUSAmylyx Pharmaceuticals | -24.35x | 1.63% | $3.97B |
ELVNUSEnliven Therapeutics | -33.20x | 2.84% | $3.77B |
TARSUSTarsus Pharmaceuticals | -5.18x | 879.07% | $3.64B |
BHCUSBausch Health | -3.69x | 511.90% | $3.10B |
XERSUSXeris Biopharma | -445.22x | -- | $2.89B |
MBXUSMBX Biosciences | -18.70x | 56.01% | $2.71B |
RGCUSRegencell Bioscience | -221.44x | -- | $2.59B |
SEPNUSSepterna | -41.41x | 56.82% | $2.44B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
